Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues of timely news and insightful strategies for reducing costs and improving outcomes, delivered by First Class U.S. Mail and electronically,
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest grouped for convenient reading
    • Bonus reports for subscribers, and
    • Regular postings from your editor.
View a sample and get more information
June 23, 2017

Recent Stories

From Drug Benefit News - New York is leading the charge among states trying to contain rising Medicaid drug prices, putting into its new state budget rules that create a drug utilization review board and cap the program’s annual drug spend. Statewide health plan groups applaud the state’s effort, but industry experts say some implications for Medicaid managed care plans remain unclear. “Currently, health plans spend more on pharmaceuticals than they do on doctors,” says spokesperson Deborah Fasser of the New York State Conference of Blue Cross Blue and Shield Plans (NYSCOP). Read more

The FDA recently approved the first versions of a generic drug to… Read more

The French drugmaker Sanofi last week became the fourth major pharmaceutical company… Read more

The pharmacy arena is “just beginning to scratch the surface” on using… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

June 12, 2017
SCOTUS Rules for Sandoz in Notice of Commercial Marketing

SCOTUS rules in Sandoz v. Amgen that applicants do not need to wait for FDA approval before giving notice of commercial marketing

March 22, 2017
Bonus Insight Reports for Subscribers

Several special reports covering key areas of concern to today’s health care executives are now available in your Subscriber Library. These original reports from the AIS Health editorial team are filled with business insights and practical advice on the pharmacy issues that affect payers and providers the most. Access them at

January 17, 2017
Long-Awaited Biosimilar Interchangeability Draft Guidance Is Out

FDA finally unveils interchangeability draft guidance for biosimilars, expects “that applications generally will include data from a switching study or studies in one or more appropriate conditions of use,” among other criteria

It's quick and easy to sign up for FREE access to!

Why do I need to register?